Search clinical trials for: Atezolizumab Placebo

Total 54373 results

Hospital of Macerata

Recruiting

International Multicentric Study ARON-1

Metastatic Renal Cell Carcinoma (mRCC)

Italy
Gladwin, Mark, MD
National Institutes of Health (NIH); National Institute on Aging (NIA)

Completed

Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age (Nitrite)

Sedentary Lifestyle | Frailty | Aging

United States
Mersin University

Completed

The Effect of Post-Cesarean Section Acupressure on the Severity of Pain and First Mobilization Distance (Acupress)

Pain | Mobilization

Turkey
Exelixis

Recruiting

Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)

Colorectal Cancer

United States, Poland, Australia, Belgium, France, Hong Kong, Korea, Republic of, Spain, Hungary, Singapore, New Zealand, Germany, Thailand, Taiwan, Portugal, United Kingdom
SCRI Development Innovations, LLC
Genentech, Inc.

Active, not recruiting

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Non-Small Cell Lung Cancer | Solid Tumor

United States
Memorial Sloan Kettering Cancer Center
University of Chicago; Genentech, Inc.; Ohio State University; Targos

Active, not recruiting

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Urothelial Carcinoma | Locally Advanced | Unresectable

United States
Vyriad, Inc.

Terminated

Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab

Recurrent Non-Small Cell Lung Cancer

United States
Megan Daly, MD
Genentech, Inc.

Active, not recruiting

Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Stage I Non-Small Cell Lung Cancer

United States
Centre Leon Berard

Recruiting

MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC)

Sarcoma,Soft Tissue

France
NeoImmuneTech
Roche Pharma AG

Active, not recruiting

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Non-Small Cell Lung Carcinoma

United States
Genentech, Inc.

Active, not recruiting

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphocytic Leukemia, Chronic | Lymphoma, Non Hodgkin

United States, Korea, Republic of, Australia, United Kingdom, Germany, Canada, Spain
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Active, not recruiting

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Bladder Cancer | Urothelial Carcinoma | Metastatic Bladder Cancer

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

Non-small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, United Kingdom, Australia, Belgium, Brazil, Canada, China, Portugal, Spain, France, Germany, Poland, Hong Kong, Israel, Thailand, Turkey, Japan, Austria, Hungary, Italy, Taiwan, Netherlands, Greece, New... and more
Grand Hôpital de Charleroi
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Active, not recruiting

Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer (R-IMMUNE)

Rectal Neoplasms

Belgium
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL (HO151DLBCL)

NHL | DLBCL

Netherlands, Belgium
Hoffmann-La Roche

Active, not recruiting

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)

Non-small Cell Lung Cancer (NSCLC)

United States, Belgium, Korea, Republic of, Canada, China, Denmark, Spain, Thailand, United Kingdom, Taiwan, Brazil, Germany, Mexico, Italy, Switzerland, Hong Kong, Japan, France, Turkey, New Zealand, Kenya, Poland
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) (IMmotion151)

Renal Cell Carcinoma

Korea, Republic of, United States, France, Italy, United Kingdom, Canada, Australia, Brazil, Denmark, Spain, Turkey, Japan, Czechia, Singapore, Thailand, Taiwan, Russian Federation, Germany, Bosnia and Herzegovina, Poland, Mexico
Hoffmann-La Roche

Completed

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma (IMmotion150)

Renal Cell Carcinoma

United States, Spain, Czechia, United Kingdom, Romania, France, Italy, Germany, Poland
University of Leicester
Eli Lilly and Company; GlaxoSmithKline; Merck Sharp & Dohme LLC; Roche Pharma AG; British Lung Foundation and other collaborators

Active, not recruiting

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (MiST)

Mesothelioma, Malignant

United Kingdom
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower150)

Carcinoma, Non-Small-Cell Lung

United States, Spain, France, Belgium, Australia, Germany, Argentina, Japan, Brazil, Italy, Singapore, Russian Federation, Taiwan, Netherlands, Peru, Chile, Latvia, Ukraine, Mexico, Lithuania, Slovakia, Bulgaria, Portugal, Austria, Swit... and more
Johns Hopkins University

Completed

Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors

Cutaneous Toxicity From ICI Therapy

United States
Oncovir, Inc.
Chevy Chase Healthcare, Chevy Chase MD; Mt. Sinai School of Medicine, New York... and other collaborators

Terminated

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Solid Cancer

United States
Hoffmann-La Roche

Completed

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

Colorectal Cancer

United States, France, Denmark, Spain
Treos Bio Limited
Mayo Clinic; Hoffmann-La Roche

Active, not recruiting

Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.

Colorectal Cancer Metastatic

United States
Sanofi

Terminated

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Neoplasm

Spain, Taiwan, Italy, Czechia, United States, Belgium, Canada, Netherlands
Matthew Galsky
Genentech, Inc.

Completed

Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

Urothelial/Bladder Cancer, Nos

United States
SQZ Biotechnologies

Completed

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Adult Solid Tumor

United States, Canada, Germany
Resverlogix Corp

Not yet recruiting

A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

Kidney Failure, Chronic
Fengmei Lian
Guang'anmen Hospital of China Academy of Chinese Medical Sciences; Hubei Hospital... and other collaborators

Unknown

Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy

Type2 Diabetes | Diabetic Non-proliferative Retinopathy
John Paul II Hospital, Krakow
National Center for Research and Development, Poland; KCRI

Completed

Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With Acute Myocardial Infarction (AMI)

Myocardial Infarction

Poland
University of Milano Bicocca
Azienda Ospedaliera San Gerardo di Monza

Recruiting

Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC (I-STOP)

Non-small Cell Lung Cancer

Italy
Fundacion Oncosur

Recruiting

Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.

Carcinoma, Small Cell Lung

Spain
Hoffmann-La Roche

Active, not recruiting

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

Hepatocellular Carcinoma

China, Japan
West German Study Group
Merck Sharp & Dohme LLC; NanoString Technologies, Inc.

Completed

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) (Keyriched-1)

Breast Cancer

Germany
Odonate Therapeutics, Inc.

Terminated

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC (CONTESSA TRIO)

Breast Cancer

United States, Korea, Republic of, Singapore
Stanford University
Yale University; Janssen Scientific Affairs, LLC

Withdrawn

Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1

PT-NANBH

United States
University of Colorado, Denver
Genentech, Inc.

Suspended

Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC

Squamous Cell Carcinoma of Head and Neck

United States
SOLTI Breast Cancer Research Group
Roche Pharma AG; Amgen

Active, not recruiting

Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (PROMETEO)

Breast Cancer

Spain
Universitaire Ziekenhuizen KU Leuven
Roche Pharma AG

Unknown

Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

Cervical Cancer

Belgium
LEO Pharma

Completed

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

Atopic Dermatitis

United States, Belgium, Canada, Australia, France, Germany, Japan, Netherlands, Poland, United Kingdom
Guang'anmen Hospital of China Academy of Chinese...
Hubei Hospital of Traditional Chinese Medicine; Hebei Yiling Hospital; The First... and other collaborators

Unknown

The Multi-Centric Clinical Study of Chinese Medicine Intervention on Diabetes Distal Symmetric Polyneuropathy.

Type 2 Diabetes Mellitus
Samsung Medical Center

Active, not recruiting

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Non-small Cell Lung Cancer

Korea, Republic of
Fondazione Ricerca Traslazionale

Not yet recruiting

Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (BEAT)

Non-small-cell Lung Cancer Patients

Italy
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Active, not recruiting

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

Triple Negative Breast Cancer | Invasive Breast Cancer | Stage IV Breast Cancer | HER2 Negative

United States
European Organisation for Research and Treatment...
Hoffmann-La Roche; Leap Therapeutics, Inc.

Withdrawn

Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer (DYNAMIC)

Esophageal Cancer | Hepatobiliary Neoplasm | Biliary Tract Cancer | GastroEsophageal Cancer
Inovio Pharmaceuticals

Active, not recruiting

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Urothelial Carcinoma

United States
Exelixis

Active, not recruiting

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001)

Renal Cell Carcinoma | Colorectal Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm Malignant

United States, Australia, Belgium, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
Hoffmann-La Roche

Completed

A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

Gynecologic Neoplasms

Spain, France, Australia, United Kingdom
National University Hospital, Singapore

Recruiting

Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.

Advanced Hepatocellular Carcinoma

Singapore
Hoffmann-La Roche

Terminated

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Stomach Neoplasms | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China

Search clinical trials for: Atezolizumab Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations